PT - JOURNAL ARTICLE AU - Sixtine Brenek AU - Stéphanie Debette AU - Sophie Auriacombe AU - Philippe Amouyel AU - Vincent Chouraki AU - Aline Meirhaeghe AU - Vincent Damotte TI - Identification of hippocampal volume as a mediator of the association between <em>APOE4</em> and dementia AID - 10.1101/2020.12.04.20242461 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.04.20242461 4099 - http://medrxiv.org/content/early/2020/12/04/2020.12.04.20242461.short 4100 - http://medrxiv.org/content/early/2020/12/04/2020.12.04.20242461.full AB - Objective To identify any mediating effect of vascular and neurodegenerative risk factors of dementia in the association existing between APOE4 and dementia.Methods 1,240 participants from the French Three City Dijon Study without prevalent tumor or dementia were included. Among these participants, 76 developed dementia during the 12 years of follow-up. Using regression and mediation analyses, we studied whether known risk factors for dementia i.e smoking status, body mass index, diabetes mellitus, hypercholesterolemia, hypertension, hippocampal volume, rate of hippocampal volume loss or white matter hyperintensities could mediate the association between APOE4 and dementia. Regression models were adjusted for age, sex, education level (and total intracranial volume when imaging metrics were considered).Results Hippocampal volume was a partial mediator of the association between APOE4 and dementia (mediation ratio = 6.7%, p=0.03). No mediation effect was found for hypercholesterolemia. No mediation analyses could be undertaken for the others factors due to the lack of their association with APOE4 in our sample.Conclusions In this study, the association between APOE4 and dementia was partially mediated by hippocampal volume, confirming a deleterious role of APOE4 in the hippocampus. This result warrants further replication in other cohorts, with higher sample sizes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by INSERM (Institut National de la Sante et de la Recherche Medicale) and the Institut Pasteur de Lille. This work has been developed and supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer s disease) including funding from MEL (Metropole europeenne de Lille), ERDF (European Regional Development Fund), Conseil Regional Nord Pas de Calais and the JPND-funded PERADES project. The Three-City Study was performed as part of collaboration between the INSERM, the Victor Segalen Bordeaux II University and Sanofi-Synthelabo. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, MGEN, Institut de la Longevite, Agence Francaise de Securite Sanitaire des Produits de Sante, the Aquitaine and Bourgogne Regional Councils, Agence Nationale de la Recherche, ANR supported the COGINUT and COVADIS projects. Fondation de France and the joint French Ministry of Research/INSERM Cohortes et collections de donnees biologiques programme. Lille Genopole received an unconditional grant from Eisai. The Three-city biological bank was developed and maintained by the laboratory for genomic analysis LAG-BRC - Institut Pasteur de Lille. The work for this manuscript was further supported by the CoSTREAM project (www.costream.eu) and funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667375.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Kremlin-Bicetre hospital approved the 3C protocol and all participants signed an informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData access can be requested through the 3C Scientific Committee (http://www.three-city-study.com)